Список литературы

1. Owen R.G. et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia//Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, N 2. P. 110 - 115.

2. Kumar S.K. et al. Macroglobulinemia/Lymphoplasmacytic Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN ). 2020.

3. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема//Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2, N 2. P. 121 - 136.

4. Varettoni M. et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in macroglobulinemia and related lymphoid neoplasms//Blood. American Society of Hematology, 2013. Vol. 121, N 13. P. 2522 - 2528.

5. Treon S.P. et al. MYD88 L265P somatic mutation in macroglobulinemia//N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, N 9. P. 826 - 833.

6. Morel P. et al. International prognostic scoring system for macroglobulinemia//Blood. 2009. Vol. 113, N 18. P. 4163 - 4170.

7. Kastritis E. et al. macroglobulinemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2018. Vol. 29, N Supp. 4. P. iv41 - iv50.

8. Kastritis E. et al. Prognostication in young and old patients with macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase//Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, N 1. P. 50 - 52.

9. Демина Е.А. et al. Общие принципы диагностики лимфом//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9 - 27.

10. Auwerda J.J.A. et al. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.//Clin. Lymphoma Myeloma. 2007. Vol. 7, N 7. P. 462 - 466.

11. Rothschild B.M., Ruhli F., Rothschild C. Skeletal clues apparently distinguishing Waldenstrom's macroglobulinemia from multiple myeloma and leukemia//Am. J. Hum. Biol. Wiley-Blackwell, 2002. Vol. 14, N 4. P. 532 - 537.

12. Rausch P.G., Herion J.C. Pulmonary manifestations of waldenstrom macroglobulinemia//Am. J. Hematol. John Wiley & Sons, Ltd, 1980. Vol. 9, N 2. P. 201 - 209.

13. Kyle R.A. et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia//Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, N 2. P. 116 - 120.

14. Owen R.G. et al. macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors//Am. J. Clin. Pathol. 2001. Vol. 116, N 3. P. 420 - 428.

15. Palladini G. et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis//Circulation. Lippincott Williams and Wilkins, 2003. Vol. 107, N 19. P. 2440 - 2445.

16. Menke M. et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with macroglobulinemia//Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, N 1. P. 100 - 103.

17. Brandefors L. et al. Prognostic factors and primary treatment for macroglobulinemia - a Swedish Lymphoma Registry study//Br. J. Haematol. Blackwell Publishing Ltd, 2018. Vol. 183, N 4. P. 564 - 577.

18. Dimopoulos M.A. et al. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.//Clin. Lymphoma. 2005. Vol. 5, N 4. P. 270 - 272.

19. Treon S.P. et al. Primary therapy of macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180//J. Clin. Oncol. 2009. Vol. 27, N 23. P. 3830 - 3835.

20. Ghobrial I.M. et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Macroglobulinemia//Am. J. Hematol. Wiley-Liss Inc., 2010. Vol. 85, N 9. P. 670 - 674.

21. Dimopoulos M.A. et al. Primary treatment of macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide//J. Clin. Oncol. 2007. Vol. 25, N 22. P. 3344 - 3349.

22. Buske C. et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)//Leukemia. Nature Publishing Group, 2009. Vol. 23, N 1. P. 153 - 161.

23. Treon S.P. et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab patients with Waldenstrom Macroglobulinemia who respond to a rituximab-containing regimen//Br. J. Haematol. 2011. Vol. 154, N 3. P. 357 - 362.

24. Chen C.I. et al. Bortezomib is active in patients with untreated or relapsed macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group//J. Clin. Oncol. 2007. Vol. 25, N 12. P. 1570 - 1575.

25. Paludo J. et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with macroglobulinemia//Ann. Hematol. Springer Verlag, 2018. Vol. 97, N 8. P. 1417 - 1425.

26. Treon S.P. et al. Long-term outcomes to fludarabine and rituximab in macroglobulinemia//Blood. 2009. Vol. 113, N 16. P. 3673 - 3678.

27. Laszlo D. et al. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed macroglobulinemia//Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, N 1. P. 130 - 132.

28. Tedeschi A. et al. Fludarabine plus cyclophosphamide and rituximab in waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease//Cancer. 2012. Vol. 118, N 2. P. 434 - 443.

29. Souchet L. et al. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia//Am. J. Hematol. Wiley-Liss Inc., 2016. Vol. 91, N 8. P. 782 - 786.

30. Kyle R.A. et al. Waldenstrom's macroglobulinemia: A prospective study comparing daily intermittent oral chlorambucil//Br. J. Haematol. 2000. Vol. 108, N 4. P. 737 - 742.

31. Treon S.P. et al. Ibrutinib monotherapy in symptomatic, patients with macroglobulinemia//J. Clin. Oncol. American Society of Clinical Oncology, 2018. Vol. 36, N 27. P. 2755 - 2761.

32. Dimopoulos M.A. et al. Update on treatment recommendations from the fourth international workshop on macroglobulinemia//Journal of Clinical Oncology. 2009. Vol. 27, N 1. P. 120 - 126.

33. Rummel M.J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial//Lancet. Lancet Publishing Group, 2013. Vol. 381, N 9873. P. 1203 - 1210.

34. Treon S.P. et al. Bendamustine therapy in patients with relapsed or refractory macroglobulinemia//Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, N 1. P. 133 - 135.

35. Treon S.P. et al. Ibrutinib in Previously Treated Macroglobulinemia. Supplemental Appendix.//N. Engl. J. Med. 2015. Vol. 372, N 15. P. 1430 - 1440.

36. Treon S.P. How I treat macroglobulinemia//Blood. 2009. Vol. 114, N 12. P. 2375 - 2385.

37. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема//Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2(2). P. 121 - 136.

38. Ioakimidis L. et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in macroglobulinemia//Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, N 1. P. 62 - 66.

39. Leblond V. et al. Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma//J. Clin. Oncol. 2013. Vol. 31, N 3. P. 301 - 307.

40. Dimopoulos M.A. et al. Treatment of waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine//Ann. Intern. Med. American College of Physicians, 1993. Vol. 118, N 3. P. 195 - 198.

41. Dimopoulos M.A. et al. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors//Ann. Oncol. 1995. Vol. 6, N 1. P. 49 - 52.